POROUS adds osteoporosis veteran to business team

By AI, Created 4:28 PM UTC, May 18, 2026, /AGP/ – Charité spin-off POROUS has named osteoporosis diagnostics pioneer Dr. Ossi Riekkinen as chief business development officer as the company pushes commercialization of its bone health technology. The hire comes as POROUS expands clinical validation across Europe and positions its ultrasound platform for markets beyond osteoporosis screening.

Why it matters: - POROUS is trying to turn a Charité-backed ultrasound platform into a broader bone health diagnostics business. - Dr. Ossi Riekkinen brings more than 20 years in osteoporosis diagnostics and deep medical-device commercialization experience. - The move supports POROUS as it works to close the gap between current bone health routines and faster measurement of treatment response, nutrition effects and fracture risk.

What happened: - POROUS GmbH appointed Dr. Ossi Riekkinen as chief business development officer. - The company announced the hire in Potsdam, Germany, on May 13, 2026. - Riekkinen previously co-founded Bone Index Finland and served as its long-time CEO. - POROUS described the appointment as part of its growth and commercialization push.

The details: - POROUS is a spin-off of Charité Universitätsmedizin Berlin. - NLC Health Ventures and Ascenion, Charité’s technology transfer partner, co-founded the company. - The company says its ultrasound backscattering technology can capture cortical bone microstructure changes within months. - POROUS says that shorter measurement window could support follow-up of treatments, nutrition, skeletal longevity and women’s health, including menopause-related care. - The company has raised more than 5 million euros in private equity. - POROUS has also received public support through the EIC Accelerator grant and ProFIT Brandenburg. - The leadership team includes CEO Julia Eschenbrenner, CTO Jonas Massmann and CFO Konstantin Hemmelrath. - POROUS is running confirmatory clinical trials at eight European sites with 2,000 participants. - The company says it has closed the first part of its Fracture Risk Study. - POROUS has been a certified medical device company since 2021 and is based in Potsdam Science Park. - The company’s LinkedIn page is available here.

Between the lines: - Riekkinen’s comments suggest POROUS is aiming beyond osteoporosis screening toward a wider prevention and monitoring platform. - NLC Health Ventures is framing osteoporosis as a large healthcare cost and a major investment theme as aging populations expand. - The focus on skeletal longevity and women’s health signals a potential commercial expansion if the clinical data continues to hold up.

What’s next: - POROUS will likely use Riekkinen’s background to accelerate partnerships, market entry and business development. - The company’s ongoing European trial program will remain central to validating the technology and supporting future commercialization. - Further progress on the Fracture Risk Study could strengthen POROUS’s case with clinicians, investors and potential customers.

The bottom line: - POROUS is adding commercial firepower at a key moment as it tries to convert a promising Charité spin-off into a broader bone health diagnostics platform.